Biguanides Market Insights: Revenue Expected to Surpass $7.55 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the biguanides market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Expected Growth Outlook For The Biguanides Market?

The market size for renin-angiotensin-system (RAS)-acting agents has experienced steady expansion in recent years. It is anticipated to increase from $5.82 billion in 2024 to $6.11 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.0%. This growth observed historically can be attributed to several factors, including the rising prevalence of hypertension, a growing incidence of cardiovascular diseases, an expanding aging population, enhanced awareness concerning blood pressure management, robust clinical research support, and the regulatory approvals for new drugs.

The market size for renin-angiotensin-system (RAS)-acting agents is anticipated to demonstrate significant growth in the upcoming years. It is projected to expand to $7.55 billion by 2029, achieving a compound annual growth rate (CAGR) of 5.4%. The expansion during the forecast period is attributable to an increased focus on personalized treatment, a rising need for fixed-dose combinations, heightened investment in cardiovascular research, greater healthcare accessibility in emerging markets, and a growing prevalence of lifestyle-related diseases. Significant trends expected in this period include artificial intelligence (AI)-driven drug development, nanotechnology-based drug delivery, advancements in personalized medicine, blockchain for secure clinical data management, wearable biosensors for hypertension monitoring, and the use of digital twin technology for patient modeling.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

Which Growth Drivers Are Propelling The Biguanides Market?

The rising incidence of hypertension is projected to boost the expansion of the renin-angiotensin system (RAS)-acting agents market moving ahead. Hypertension, also known as elevated blood pressure, represents an ongoing medical state where the pressure of blood against arterial walls remains persistently excessive. The increase in hypertension cases stems from poor dietary choices, especially foods rich in salt and processed ingredients, leading to heightened blood pressure and stress on the heart and blood vessels. Renin-angiotensin system (RAS)-acting agents contribute to lessening hypertension by managing blood pressure; they achieve this by blocking angiotensin II, a hormone responsible for narrowing blood vessels and raising fluid retention, which in turn encourages vessel widening and decreases blood pressure. As an illustration, data from October 2024, released by the Australian Bureau of Statistics, an Australia-based government entity, indicated that 11.6% (3.0 million) of Australians experienced hypertension in 2022, with comparable figures for men (11.7%) and women (11.6%). Consequently, the growing occurrence of hypertension is propelling the expansion of the renin-angiotensin system (RAS)-acting agents market.

Which Segmentation Factors Are Most Significant In The Biguanides Market Analysis?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

What New Opportunities Are Emerging From Trends In The Biguanides Market?

Leading companies within the renin-angiotensin system (RAS)-acting agents market are prioritizing the creation of innovative renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors. Their aim is to boost effectiveness, mitigate adverse reactions, enhance patient adherence, and treat hypertension, heart failure, and kidney diseases. An angiotensin-converting enzyme (ACE) inhibitor operates as a drug that reduces blood pressure by inhibiting the enzyme responsible for transforming angiotensin I into angiotensin II, a compound known for constricting blood vessels. A notable example occurred in November 2023, when Proveca Ltd., a UK-based pharmaceutical company, obtained a grant from the European Commission. This grant was for pediatric use marketing authorization (PUMA) concerning Aqumeldi (enalapril maleate) orodispersible tablets, which are prescribed for managing heart failure in children from birth to less than 18 years. Aqumeldi, which functions as an angiotensin-converting enzyme (ACE) inhibitor, addresses pediatric heart failure by obstructing the angiotensin-converting enzyme (ACE), thus halting the conversion of angiotensin I to angiotensin II. This mechanism leads to the relaxation of blood vessels, improved blood flow, and a reduced burden on the heart.

Who Are The Most Influential Companies In The Biguanides Market?

Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

Which Region Holds The Largest Share In The Biguanides Market Today?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

Browse Through More Reports Similar to the Global Biguanides Market 2025, By The Business Research Company

Blood And Blood Components Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Wearable Blood Pressure Monitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wearable-blood-pressure-monitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795